Showing 3631-3640 of 5646 results for "".
- Ophthalmic Industry Veteran Scott Hunter Passes Awayhttps://modernod.com/news/ophthalmic-industry-veteran-scott-hunter-passes-away/2482564/Longtime ophthalmic industry leader Scott Hunter passed away on December 3, Neurotech announced. Mr. Hunter was the Chief Commercial Officer of Neurotech, a position he held since January 2023. “The entire Neurotech family mourns this loss. On behalf of the Board of Directors, man
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- Alcon Expands TOTAL30 for Astigmatism Offerings with New Parametershttps://modernod.com/news/alcon-expands-total30-for-astigmatism-offerings-with-new-parameters-to-enhance-comfort-and-accessibility/2482553/Alcon announced the availability of expanded parameters for TOTAL30 for Astigmatism. As the first and only monthly replacement Water Gradient toric contact lens, TOTAL30 is designed to deliver a
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopiahttps://modernod.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective
- Samsung Bioepis and Biogen Announce EC Approval of Eylea Biosimilar Opuvizhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ec-approval-of-eylea-biosimilar-opuviz/2482545/Samsung Bioepis and Biogen jointly announced that the European Commission (EC) has granted approval for Opuviz 40 mg/mL for injection in a vial. The biosimilar, also known as SB15, references the established treatment Eylea (aflibercept) and was developed by Samsung Bioepis. T
- Eyenovia's Late-Stage Pediatric Myopia Treatment Fails to Meet Primary Endpointhttps://modernod.com/news/eyenovias-late-stage-pediatric-myopia-treatment-fails-to-meet-primary-endpoint/2482544/Eyenovia announced that its phase 3 CHAPERONE study failed to meet its primary endpoint. The study was investigating Eyenovia’s proprietary drug-device combination, using low-dose atropine dispensed through the company's Optejet platform, as a potential treatment for pediatric
- Oklahoma Neonatologist-Researcher Earns NIH Grant to Advance Retinopathy of Prematurityhttps://modernod.com/news/oklahoma-neonatologist-researcher-earns-nih-grant-to-advance-retinopathy-of-prematurity/2482537/Faizah Bhatti, MD, was the first to discover the presence of surfactant protein A in the eye–a key protein related to blood vessel growth and previously believed to only exist in the lung. Now, the University of Oklahoma neonatologist and researcher has earned a 5-year, $2.3 million grant f
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- Konan Medical USA Launches objectiveFIELD Visual Field Analyzerhttps://modernod.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/Konan Medical USA announced the commercial launch of its objectiveFIELD (OFA) visual field analyzer. The OFA is an objective visual field analyzer designed to detect visual field abnormalities using pupillary responses. According to Konan Medical, unlike traditional subjectiv